Interesting.
"Following a positive interim Phase I readout, AbbVie is exercising an option to acquire TeneoOne and its BCMA candidate TNB-383B for relapsed or refractory multiple myeloma.
AbbVie inked a deal with TeneoOne back in 2019 to develop and commercialize TNB-383B, a bispecific antibody that targets BCMA and CD3. The treatment is designed to direct the body’s immune system against BCMA-expressing tumor cells. And according to interim results, the candidate showed a 79% objective response rate in a Phase I study. Sixty-three percent of patients saw a “very good partial response” or better, and 29% saw a complete response at doses greater than or equal to 40 mg at a median follow-up of 6.1 months.
"While other BCMA and CD3 bispecific therapies require weekly administration, the recommended Phase 2 dose of TNB-383B will investigate infrequent dosing of every 3 weeks for intravenous administration, which is an important treatment factor for people living with multiple myeloma,” AbbVie’s vice chairman and president Michael Severino said in a statement.
At the interim analysis, 103 participants had been dosed with TNB-383B. The trial is being conducted in patients who have had at least three prior lines of treatment.
The results allowed the AbbVie team to “make this decision with confidence," Severino said. — Nicole DeFeudis"
https://endpts.com/abbvie-snaps-up-a-bi ... k-program/
AbbVie snaps up a bispecific for multiple myeloma in TeneoOne buyout
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam